Rheumatology

Drug Allergy

Questions discussed in this category

Is it safe to use one TNF inhibitor (e.g., infliximab) in a patient who has had a severe allergic reaction to a different TNF inhibitor (e.g., adalimumab)?

1 Answer available

Have you been able to safely use other bisphosphonates in patients who developed an allergic reaction (angioedema) to fosamax?

1 Answer available

What are best practices in management of severe acute infusion reaction from infliximab?

Patient became acutely flushed, developed severe and prolonged hypotension with brief loss of consciousness, dizziness, nausea, dry heaves and headach...

1 Answer available

Do you recommend allopurinol desensitization in gout patients who develop a rash on allopurinol therapy?

2 Answers available

How do you advise patients who had autoimmune diseases "triggered" by COVID infections on getting COVID vaccination?

E.g., inflammatory polyarthritis or inflammatory myopathy with onset within 2 weeks of documented COVID infection

1 Answer available

Is it okay to use medications associated with drug-induced lupus in patients with SLE?

1 Answer available

For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?

1 Answer available

How does your treatment algorithm differ for drug-induced ANCA vasculitis compared to non drug-induced ANCA vasculitis in cases with severe/organ-threatening manifestations?

1 Answer available

Papers discussed in this category

The journal of allergy and clinical immunology. In practice, 2017

Reactions to Rituximab in an Outpatient Infusion Center: A 5-Year Review.

Lancet Rheumatol, 2021 Apr 06

Incident systemic rheumatic disease following COVID-19.

N Engl J Med, 2020 Nov 20

Covid-19-Associated Myopathy Caused by Type I Interferonopathy.

The New England journal of medicine, 2018-03-29

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.

Lancet, 2020 Nov 09

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.

The American journal of gastroenterology, 2003 Jun

The incidence and management of infusion reactions to infliximab: a large center experience.

The Journal of rheumatology, 2015 Jun 15

Incidence and Management of Infusion Reactions to Infliximab in a Prospective Real-world Community Registry.

Rheumatology

Drug Allergy

Questions discussed in this category

Papers discussed in this category

Related Topics in Rheumatology